Wu X, et al. - Researchers compared entecavir (Etv) monotherapy with combination therapy [a de novo combination of lamivudine (Lam) and adefovir (Adv)] regarding their efficacy and safety in patients with hepatitis B virus (HBV)-related compensated liver cirrhosis. They analyzed a total of 578 patients with HBV-related compensated liver cirrhosis; 485 were recruited in Etv group, 93 were recruited in the combination group. Outcomes revealed less virological breakthrough and potentially higher HBV-DNA suppression with Etv treatment when compared to de novo combination of Lam and Adv during 3 years in these patients.